Term Efficacy Of Sorafenib Combined Antiretroviral Therapy In Advanced Hbv-Related Liver Cancer

OBJECTIVE Reasonable and necessary to explore the impact of recent sorafenib combined anti-HBV therapy for hepatitis B virus infection in patients with advanced hepatocellular carcinoma efficacy for these patients treated with sorafenib combined anti-HBV therapy to provide a theoretical basis for the joint observation term efficacy of antiviral therapy for hepatitis B associated with advanced liver cancer combined, and investigate the effects of anti-HBV therapy on the drug side effects of sorafenib.METHODS Collected during2008-2013in Affiliated Tumor Hospital of Guangxi Medical University information complete oral targeted therapy sorafenib simultaneously anti-HBV therapy in HCC patients, treated at the same time collecting data over the same period a complete oral sorafenib alone targeted therapy clinical data did not undergo anti-HBV therapy for HCC patients as controls. According to the same period of anti-HBV therapy is divided into group A and group B. Comparison of the two groups of tumor treatment, liver function, survival, and other indicators of adverse reactions in patients.RESULTS A group and B group differences in age, gender, pre-treatment liver function Child-Pugh grade, tumor size (maximum diameter), number, thrombosis, before treatment TBIL, ALT, AFP, and other aspects of TACE treatment if the line had no statistics significance (P>0.05). Three months, six months, efficacy comparison:P values were greater than0.05, but slightly higher than the rate of group B SD and PD A group rate is slightly lower than the A group. The main adverse reactions:rash, hand-foot syndrome, hypertension, diarrhea, liver damage, differences were not statistically different (P>0.05).CONCLUSION Sorafenib combination antiretroviral therapy may prolong sorafenib in patients with HBV-related advanced liver cancer survival time, without increasing adverse reactions and reduced quality of life.